Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Feedback
  • Other Publications
    • Pharmacological Reviews

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Pharmacological Reviews
  • My alerts
  • Log in
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Feedback
Review ArticleReview Article

Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+?

Carles Cantó and Johan Auwerx
Beatrice Desvergne, ASSOCIATE EDITOR
Pharmacological Reviews January 2012, 64 (1) 166-187; DOI: stonel.info/10.1124/pr.110.003905
Carles Cantó
Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Auwerx
Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beatrice Desvergne
Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Sirtuin 1 (SIRT1) is an evolutionarily conserved NAD+-dependent deacetylase that is at the pinnacle of metabolic control, all the way from yeast to humans. SIRT1 senses changes in intracellular NAD+ levels, which reflect energy level, and uses this information to adapt the cellular energy output such that it matches cellular energy requirements. The changes induced by SIRT1 activation are generally (but not exclusively) transcriptional in nature and are related to an increase in mitochondrial metabolism and antioxidant protection. These attractive features have validated SIRT1 as a therapeutic target in the management of metabolic disease and prompted an intensive search to identify pharmacological SIRT1 activators. In this review, we first give an overview of the SIRT1 biology with a particular focus on its role in metabolic control. We then analyze the pros and cons of the current strategies used to activate SIRT1 and explore the emerging evidence indicating that modulation of NAD+ levels could provide an effective way to achieve such goals.

Footnotes

  • This article is available online at http://stonel.info.

    .

  • © 2012 by The American Society for Pharmacology
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Pharmacological Reviews: 64 (1)
Pharmacological Reviews
Vol. 64, Issue 1
1 Jan 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+?
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
Citation Tools
Review ArticleReview Article

TARGETING SIRT1 TO IMPROVE METABOLISM: ALL YOU NEED IS NAD+?

Carles Cantó and Johan Auwerx
Pharmacological Reviews January 1, 2012, 64 (1) 166-187; DOI: stonel.info/10.1124/pr.110.003905

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Review ArticleReview Article

TARGETING SIRT1 TO IMPROVE METABOLISM: ALL YOU NEED IS NAD+?

Carles Cantó and Johan Auwerx
Pharmacological Reviews January 1, 2012, 64 (1) 166-187; DOI: stonel.info/10.1124/pr.110.003905
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Introduction
    • II. Sirtuin 1 in a Nutshell
    • III. Sirtuin 1 and Metabolic Disease: Evidence from Mice Models
    • IV. Physiological and Pharmacological Modulation of Sirt1 Activity
    • V. Conclusions and Future Directions
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Dose-Response-Time Data Analysis
  • Volume-Activated and Volume-Correlated Anion Channels
  • The Study of Taste as an Extension of Pharmacology
Show more Review Articles

Similar Articles

Узнайте про авторитетный web-сайт , он описывает в статьях про промышленный альпинизм киев www.cleansale.kiev.ua
Этот важный веб сайт на тематику охрана массовых мероприятий охрана-киев.com.ua/
www.xn----htbbbqamuljibcwx0bn.com
  • Home
  • Alerts
      RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback

More Information

  • Editorial Board
  • Instructions to Authors
  • Customized Alerts
  • RSS Feeds

ASPET's Other Journals

(Online)

Copyright © 2019 Pharmacology